Overview - Production Animal Markets – Poultry & Pigs
Imugene is developing and commercialising a range of biological animal health vaccines for the pig and poultry production animal markets worldwide.
The Imugene 'Vector' vaccines improve the health and welfare of animals and reduce or eliminate the use of chemicals and drugs, particularly antibiotics, in intensively reared ‘food’ animals.
Imugene’s vaccines improve pig and chicken health, resulting in the delivery of productivity and economic gains to the poultry and pig industries through the prevention of specific infectious diseases of economic importance.
Our disease control vaccines utilise the animal or birds own natural immune system and are safe, residue free, non-antibiotic, non-drug (chemical) treatments. Importantly, they are cost effective to manufacture and administer which is paramount within the cost conscious intensive pig and poultry farming industries.
In response to the growing problem of bacterial antibiotic resistance, international health organisations and governments are phasing out the use of antibiotics as growth promotants in food producing animals. Accordingly, biological treatments are being increasingly used in the prevention and treatment of disease as well as overall growth enhancement.
The platform technologies – the Porcine Adenoviral Delivery Vector (PAV) and the Fowl Adenoviral Delivery Vector (FAV) is patent protected in most global markets. The Vectors are exclusively owned under a worldwide license from the CSIRO (Australian Government Research organization) or owned, in the case of a US Porcine Patent, by Imugene.
Imugene’s biological productivity enhancers and specific disease vaccines are economically viable alternatives to the current use of in feed antibiotics for growth promotion and disease prevention for the poultry and pig industries.
Importantly, Imugene’s products reduce the level of chemical and antibiotic residue entering the human food chain.